Outrun Therapeutics, based in Dundee, Scotland, develops small-molecule drugs targeting E3 ligases with a focus on protein stabilisation. The company has built a proprietary discovery platform that quantitatively assesses the specificity and selectivity of E3 ligase targets to reduce discovery time and improve target binding. It also uses engineered protein sensors (EPS) to reveal detailed E3 ligase biochemistry, enabling discovery of molecules with potentially superior binding, specificity, and activity. Outrun describes its approach as a scalable and modular strategy for developing inhibitors that stabilise proteins. The company raised $10M in seed financing and plans to use the funds to expand operations and its R&D sector. Outrun is led by CEO Dr Carolyn Porter.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2024